Yeni Nesil Oral Antikoagulanların İlaç İlaç Etkileşimleri ve Güvenliliğinin Değerlendirilebilmesi İçin Hayvan Modellerinin Geliştirilmesi, Kullanımı ve Bulunabilirliği

Direkt oral antikoagulanlar (DOAK’lar), yeni, thrombine veya aktive faktör Xa’ya selektif olan direkt etkili ilaçlardır. Bu yeni oral antikoagulan ilaçların, klasik antikoagulan ilaçlara göre hastalar açısından çok sayıda avantajları vardır (izleme ihtiyacının olmaması, geniş tedavi penceresi vbg.). Yakın geçmişte, direkt oral antikoagulanlar, tromboembolizmi önleme ve tedavisinde K vitamini antagonistlerine alternatif olarak sunulmuşlardır. DOAKların ana kullanım alanı, atrial fibrilasyonlu hastalarda inmenin önlenmesidir. Ancak, öte yandan, DOAK’ların diğer ilaçlar ile kombine kullanımı sırasında ilaç-ilaç etkileşimleri oluşabilmekte ve güvenlilik profilleri henüz yeterli düzeyde bilinmemektedir. Günümüzde, DOAK’ların ilaç-ilaç etkileşimi ve güvenliliğini araştırmada kullanılan hayvan modelleri henüz yeterli değildir. Bu derlemenin amacı, DOAK’ların ilaç-ilaç etkileşimi ve güvenliliğini araştıran hayvan modellerinin daha da geliştirilmesi, kullanımı ve bulunabilirliğidir.

Availability, Use and Development of Animal Models for the Assessment of Drug-Drug Interactions and Safety of Direct Oral Anticoagulants

Direct oral anticoagulants (DOACs) are novel, direct acting drugs that are selective for either thrombin or activated factor X. Due to theirobvious benefits for patients (broader therapeutic window, are not routinely monitored etc.), they are increasingly used as an alternativeto vitamin K antagonists. One of the major indications for the use of DOACs is the stroke prevention in patients with atrial fibrillation (AF).Although, the DOAC use becomes extensive in the clinical area especially cardiology, many drug drug interactions occur when DOACs areused with other drugs. Also, the safety profile of DOACs is still to be investigated. Animal models can be used to investigate the drug druginteractions and safety of DOACs under standart laboratory conditions. Unfortunately, there is not sufficient data that investigates the drugdrug interactions and safety of DOACs in animal models. The focus of this review will be the availability, use and development of animalmodels to assess drug drug interactions and safety profile of DOACs.

PDF

___

Shih AW, Crowther MA: Reversal of direct oral anticoagulants: A practical approach. Hematology Am Soc Hematol Educ Program, 2016 (1): 612-619, 2016. DOI:10.1182/asheducation-2016.1.612
Vargas M, Marra A, Perrone A, Servillo G: Bleeding management in patients with new oral anticoagulants. Minerva Anestesiol, 82 (8): 884- 894, 2016.
Proietti M, Lip GYH: Antidotes to non-vitamin K oral anticoagulants: Necessary or not? Expert Opin Pharmacother, 16 (11): 1573-1576, 2015. DOI: 10.1517/14656566.2015.1057119
Hu TY, Vaidya VR, Asirvatham SJ: Reversing anticoagulant effects of novel oral anticoagulants: Role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag, 12, 35-44, 2016. DOI: 10.2147/ VHRM.S89130
Pollack CV Jr, Bernstein R, Dubiel R, Reilly P, Gruenenfelder F, Huisman MV, Kam CW, Kleine E, Levy JH, Sellke FW, Steiner T, Ustyugova A, Weitz JI: Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. J Med Econ, 20 (5): 435-442, 2017. DOI: 10.1080/13696998.2016.1273229
Rahmat NA, Lip GYH: Monitoring the effects and antidotes of the non-vitamin K oral anticoagulants. Arrhythm Electrophysiol Rev, 4 (1): 90- 95, 2015. DOI: 10.15420/aer.2015.04.02.90
Reddy ST, Cossey TC, Savitz SI, Grotta JC: Non-vitamin K oral anticoagulants (NOACs) and their reversal. Curr Neurol Neurosci Rep, 17 (9): 67, 2017. DOI: 10.1007/s11910-017-0774-6
Ansell JE: Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J Thromb Thrombolysis, 41 (2): 248-252, 2016. DOI: 10.1007/s11239-015-1288-1
Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H, Koren G: Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol, 123, 1256-1261, 2014. DOI: 10.1097/AOG.0000000000000277
Margelidon-Cozzolino V, Hodin S, Jacqueroux E, Delézay O, Bertoletti L, Delavenne X: In vitro assessment of pharmacokinetic drug drug ınteractions of direct oral anticoagulants: Type 5-phosphodiesterase ınhibitors are ınhibitors of rivaroxaban and apixaban efflux by P-glycoprotein. J Pharmacol Exp Ther, 365 (3): 519-525, 2018. DOI: 10.1124/jpet.117.245993
Gacar N, Gocmez S, Utkan T, Gacar G, Komsuoglu I, Tugay M, Utkan NZ: Effects of resveratrol on ileal smooth muscle reactivity in polymicrobial sepsis model. J Surg Res, 174 (2): 339-343, 2012. DOI: 10.1016/j.jss.2010.12.015
Yazir Y, Gocmez SS, Utkan T, Komsuoglu-Celikyurt I, Gacar N, Sarioglu Y: Effects of chronic low- and high-dose ethanol intake on the nitrergic relaxations of corpus cavernosum and penile nitric oxide synthase in the rabbit. Int J Impot Res, 24 (5): 185-190, 2012. DOI: 10.1038/ ijir.2012.14
Komsuoglu Celikyurt IK, Kayir H, Ulak G, Erden FB, Ulusoy GK, Uzbay TI: Effects of risperidone, quetiapine and ziprasidone on ethanol withdrawal syndrome in rats. Prog Neuropsychopharmacol Biol Psychiatry, 35 (2): 528-536, 2011. DOI: 10.1016/j.pnpbp.2010.12.009
Komsuoglu Celikyurt I, Utkan T, Ozer C, Gacar N, Aricioglu F: Effects of YC-1 on learning and memory functions of aged rats. Med Sci Monit Basic Res, 20, 130-137, 2014. DOI: 10.12659/MSMBR.891064
Komsuoglu Celikyurt I, Mutlu O, Ulak G, Uyar E, Bektas E, Yildiz Akar F, Erden F, Tarkun I: Exenatide treatment exerts anxiolytic- and antidepressant-like effects and reverses neuropathy in a mouse model of type-2 diabetes. Med Sci Monit Basic Res, 20, 112-117, 2014. DOI: 10.12659/ MSMBR.891168
Lu G, Hollenbach SJ, Baker DC, Tan S, Hutchaleelaha A, Curnutte JT, Conley PB: Preclinical safety and efficacy of andexanet alfa in animal models. J Thromb Haemost. 15 (9): 1747-1756, 2017. DOI: 10.1111/ jth.13768
Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U: A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med, 194, 446-451, 2013. DOI: 10.1038/nm.3102
Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer KH, Straub A: In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. J Thromb Haemost, 3 (3): 514-521, 2005. DOI: 10.1111/j.1538- 7836.2005.01166.x
Honickel M, Braunschweig T, Rossaint R, Stoppe C, Ten Cate H, Grottke O: Reversing dabigatran anticoagulation with prothrombin complex concentrate versus idarucizumab as part of multimodal hemostatic intervention in an animal model of polytrauma. Anesthesiology, 12 (5): 852-861, 2017. DOI: 10.1097/ALN.0000000000001856
Grottke O, van Ryn J, Spronk HMH, Rossaint R: Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care,181: R27, 2014. DOI: 10.1186/cc13717
Pragst I, Zeitler SH, Doerr B, Kaspereit FJ, Herzog E, Dickneite G, van Ryn J: Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. J Thromb Haemost, 10 (9): 1841-1848, 2012. DOI: 10.1111/j.1538-7836.2012.04859.x
Sheffield WP, Lambourne MD, Eltringham-Smith LJ, Bhakta V, Arnold DM, Crowther MA: γT‐S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo. J Thromb Haemost, 127, 1110- 1115, 2014. DOI: 10.1111/jth.12601
van Ryn J, Schurer J, Kink-Eiband M, Clemens A: Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation. Anesthesiology, 120, 1429-1440, 2014. DOI: 10.1097/ALN.0000000000000255
Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP: Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate. J Thromb Haemost, 10 (9): 1830-1840, 2012. DOI: 10.1111/j.1538-7836.2012.04863.x
Zhou W, Zorn M, Nawroth P, Butehorn U, Perzborn E, Heitmeier S, Veltkamp R: Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke, 44 (3): 771-778, 2013. DOI: 10.1161/STROKEAHA.112.675231
Honickel M, Akman N, Grottke O: The reversal of direct oral anticoagulants in animal models. Shock, 48 (2): 144-158, 2017. DOI: 10.1097/ SHK.0000000000000848
Leong XF, Ng CY, Jaarin K: Animal models in cardiovascular research: Hypertension and atherosclerosis. Biomed Res Int, 2015: 528757, 2015. DOI: 10.1155/2015/528757
Lau YC, Lip GYH: Which drug should we use for stroke prevention in atrial fibrillation? Curr Opin Cardiol, 29 (4): 293-300, 2014. DOI: 10.1097/ HCO.0000000000000065
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 361 (12): 1139-1151, 2009. DOI: 10.1056/NEJMoa0905561
Eriksson BI, Quinlan DJ, Weitz JI: Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet, 48 (1): 1-22, 2009. DOI: 10.2165/ 0003088-200948010-00001
Abo-Salem E, Becker RC: Reversal of novel oral anticoagulants. Curr Opin Pharmacol, 27, 86-91, 2016. DOI: 10.1016/j.coph.2016.02.008
Celikyurt I, Meier CR, Kühne M, Schaer B: Safety and interactions of direct oral anticoagulants with antiarrhythmic drugs. Drug Saf, 40 (11): 1091-1098, 2017. DOI: 10.1007/s40264-017-0567-5
Yeh CH, Hogg K, Weitz JI: Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol, 35 (5): 1056- 1065, 2015. DOI: 10.1161/ATVBAHA.115.303397
Mekaj YH, Mekaj AY, Duci SB, Miftari EI: New oral anticoagulants: Their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag, 24 (11): 967-977, 2015. DOI: 10.2147/TCRM.S84210